Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Female
NCT04407078Completed
- Sponsor
- Ajou University School of Medicine
- Start
- Dec 2019
- Primary completion
- Jan 2021
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Sugammadex in Gallbladder diseases (2 arms), sponsored by Ajou University School of Medicine. Primary endpoint: Optimal effect-site concentration of remifentanil. Started Dec 2019; status: completed.
02
Drugs
Sugammadex
03
Conditions
Gallbladder diseases
Beyond the preview
Go deeper on NCT04407078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04407078.